Insider Selling: James G. Marken Unloads 5,000 Shares of ANI Pharmaceuticals Stock (ANIP)
ANI Pharmaceuticals (NASDAQ:ANIP) VP James G. Marken sold 5,000 shares of the stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $34.28, for a total value of $171,400.00. Following the completion of the transaction, the vice president now directly owns 46,568 shares in the company, valued at approximately $1,596,351. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded down 1.03% on Thursday, hitting $35.44. The stock had a trading volume of 60,828 shares. ANI Pharmaceuticals has a 52 week low of $4.80 and a 52 week high of $38.74. The stock has a 50-day moving average of $31.72 and a 200-day moving average of $26.58. The company has a market cap of $399.8 million and a price-to-earnings ratio of 257.63.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Monday, May 5th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $11.40 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. The company’s revenue for the quarter was up 94.6% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals will post $1.74 earnings per share for the current fiscal year.
ANIP has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of ANI Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, May 21st. They now have a $35.20 price target on the stock. Separately, analysts at Roth Capital raised their price target on shares of ANI Pharmaceuticals from $36.00 to $38.00 in a research note on Tuesday, May 6th.
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.